AUTHOR=Puertas Borja , Rey-Búa Beatriz , Eiros Rocío , Martín-Arribas Alberto , Montero-Mateos Enrique , Hernández-Sánchez Alberto , Gómez-Úbeda Sandra , Alejo-Alonso Elena , Martín-López Ana A. , Antúnez Patricia , Villacorta-Argüelles Eduardo , Gallego-Delgado María , Puig Noemi , Mateos María-Victoria , González-Calle Verónica 

TITLE=Case Report: Renal relapse after heart transplantation, induction, and autologous stem cell transplantation in a patient with AL amyloidosis with exclusive cardiac involvement

JOURNAL=Frontiers in Hematology

VOLUME=Volume 1 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/hematology/articles/10.3389/frhem.2022.997262

DOI=10.3389/frhem.2022.997262

ISSN=2813-3935

ABSTRACT=Currently, the daratumumab, cyclophosphamide, bortezomib and dexamethasone regimen is the standard of care for patients with AL amyloidosis. However, there is no consensus for treatment in patients with relapsed/refractory AL amyloidosis. Furthermore, there is no recommendation on what salvage therapy is optimal in the solid organ recipient with AL amyloidosis, such as a heart transplant. With this case we illustrate how treatment with daratumumab may be effective and safe in a patient with renal involvement at the relapse in a patient with AL amyloidosis after heart transplantation and autologous stem cell transplantation.